-
Shilpa Medicare gets initial authorization from EMA for Rivaroxaban Orodispersible Films
23 Sep 2025 10:55 GMT
… version of the innovator product Xarelto, from Bayer AG, which is available … bioequivalent to the reference product Xarelto and is a Rivaroxaban in … Transdermal Patches.
Shilpa Medicare is a global pharmaceutical company specializing in contract …
-
Shilpa Medicare Ltd receives initial authorization for Rivaroxaban Orodispersible Films from Europe
23 Sep 2025 08:58 GMT
… of the innovator product Xarelto®, from Bayer AG, which is available … Films is an anticoagulant medicine (a medicine that prevents blood clotting …
Keywords
ShilpaMedicare
INE790G01031
Pharmaceuticals
InitialAuthorization
EMA
Rivaroxaban
OrodispersibleFilms
-
Shilpa Medicare shares jump over 4% as EMA grants nod for Rivaroxaban Orodispersible Films
23 Sep 2025 07:49 GMT
… generic version of Bayer AG’s Xarelto®.
The product is … reference drug. Rivaroxaban is prescribed for the treatment and … prevention of various thrombotic conditions.
Shilpa Medicare … milestone for Shilpa Medicare’s specialty generics portfolio …
-
Bayer CEO: overhaul is leading to pharma pipeline boost
22 Sep 2025 11:12 GMT
… San Sebastian, Spain, Anderson said Bayer had fundamentally redesigned itself and … cancer drug Nubeqa and kidney treatment Kerendia were strong, and heart drug Beyonttra … stroke prevention pill Xarelto and for an older version of eye drug Eylea …
-
Bayer moves Parkinson’s cell therapy into Phase III trial
22 Sep 2025 10:32 GMT
… the near term, Bayer’s pharmaceutical unit is banking on … new prostate cancer drug Nubeqa, kidney treatment Kerendia and a … prevention drug Xarelto and an older version of eye medication Eylea. … Cambridge University, U.S. biotech firm Aspen Neuroscience, and …
-
Human medicines European public assessment report (EPAR): Rivaroxaban Koanaa, rivaroxaban, Status: Opinion
19 Sep 2025 10:30 GMT
… a marketing authorisation for the medicinal product Rivaroxaban Koanaa, intended … bioequivalence to the reference product Xarelto.
The full indications for Rivaroxaban … unstable PE patients).
Paediatric population
Treatment of venous thromboembolism (VTE) and …
-
CSL nabs option to acquire a startup and its blood-clotting drug
16 Sep 2025 15:50 GMT
… acquisition of a Dutch biotechnology startup.
Under the … and spinning off its vaccine business, Seqirus. The … 2024. The drug’s original developer, Portola Pharmaceuticals, had … trials. Bristol Myers and Johnson & Johnson are testing a similar medicine.
-
Appeals court rejects NJ pharma challenges to Medicare drug pricing (updated)
15 Sep 2025 20:19 GMT
… Centers for Medicare and Medicaid Services can directly negotiate with pharmaceutical companies over … .
Medications from many New Jersey drug makers – including Eliquis (Bristol-Myers Squibb), Xarelto (Johnson …
-
[Latest] Global Pharmaceutical Metal Detector Market Size/Share Worth USD 270.93 Billion by 2034 at a 5.28% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
11 Sep 2025 18:20 GMT
… high-quality medicines that are … Hemorrhage Treatment), By Distribution Channel (Hospital Pharmacies, Drug … Provider (Hospitals, Pharmaceutical & Biotech Companies, Research Institutes … By Drug Type (Dabigatran (Pradaxa), Rivaroxaban (Xarelto), Apixaban …
-
Stop now - 4 medications you should never take with Omega-3 supplements, experts warn
11 Sep 2025 20:03 GMT
… also use prescription or other medications.
Omega-3s are nutritional rich … aids in cardiovascular health, specific medications can overlap or amplify these … (Blood Thinners)Medications like warfarin (Coumadin), Eliquis, and Xarelto lower clotting issues …